Prediction of Alzheimer's disease biomarker status defined by the 'ATN framework' among cognitively healthy individuals: results from the EPAD longitudinal cohort study

被引:26
|
作者
Calvin, Catherine M. [1 ]
de Boer, Casper [2 ]
Raymont, Vanessa [1 ]
Gallacher, John [1 ]
Koychev, Ivan [1 ]
机构
[1] Univ Oxford, Dept Psychiat, Warneford Hosp, Oxford OX3 7JX, England
[2] Amsterdam UMC, Alzheimer Ctr Amsterdam, Amsterdam, Netherlands
基金
英国医学研究理事会;
关键词
ATN framework; Risk scores; White matter lesions volume; VASCULAR RISK-FACTORS; AA RESEARCH FRAMEWORK; DEMENTIA RISK; BIOLOGICAL DEFINITION; SERUM-CHOLESTEROL; PHYSICAL-ACTIVITY; MIDLIFE; PROFILE; PATHOLOGIES; VALIDATION;
D O I
10.1186/s13195-020-00711-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The Amyloid/Tau/Neurodegeneration (ATN) framework has been proposed as a means of evidencing the biological state of Alzheimer's disease (AD). Predicting ATN status in pre-dementia individuals therefore provides an important opportunity for targeted recruitment into AD interventional studies. We investigated the extent to which ATN-defined biomarker status can be predicted by known AD risk factors as well as vascular-related composite risk scores. Methods One thousand ten cognitively healthy older adults were allocated to one of five ATN-defined biomarker categories. Multinomial logistic regression tested risk factors including age, sex, education, APOE4, family history of dementia, cognitive function, vascular risk indices (high systolic blood pressure, body mass index (BMI), high cholesterol, physical inactivity, ever smoked, blood pressure medication, diabetes, prior cardiovascular disease, atrial fibrillation and white matter lesion (WML) volume), and three vascular-related composite scores, to predict five ATN subgroups; ROC curve models estimated their added value in predicting pathology. Results Age, APOE4, family history, BMI, MMSE and white matter lesions (WML) volume differed between ATN biomarker groups. Prediction of Alzheimer's disease pathology (versus normal AD biomarkers) improved by 7% after adding family history, BMI, MMSE and WML to a ROC curve that included age, sex and APOE4. Risk composite scores did not add value. Conclusions ATN-defined Alzheimer's disease biomarker status prediction among cognitively healthy individuals is possible through a combination of constitutional and cardiovascular risk factors but established dementia composite risk scores do not appear to add value in this context.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study
    Catherine M. Calvin
    Casper de Boer
    Vanessa Raymont
    John Gallacher
    Ivan Koychev
    Alzheimer's Research & Therapy, 12
  • [2] Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals
    Milne, Richard
    Bunnik, Eline
    Diaz, Ana
    Richard, Edo
    Badger, Shirlene
    Gove, Dianne
    Georges, Jean
    Fauria, Karine
    Molinuevo, Jose-Luis
    Wells, Katie
    Ritchie, Craig
    Brayne, Carol
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 62 (02) : 487 - 498
  • [3] Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups
    Dubbelman, Mark A.
    Hendriksen, Heleen M. A.
    Harrison, John E.
    Vijverberg, Everard G. B.
    Prins, Niels D.
    Kroeze, Lior A.
    Ottenhoff, Lois
    Van Leeuwenstijn, Mardou M. S. S. A.
    Verberk, Inge M. W.
    Teunissen, Charlotte E.
    van de Giessen, Elsmarieke M.
    Van Harten, Argonde C.
    van der Flier, Wiesje M.
    Sikkes, Sietske A. M.
    NEUROLOGY, 2024, 102 (02)
  • [4] Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study
    Burnham, Samantha C.
    Bourgeat, Pierrick
    Dore, Vincent
    Savage, Greg
    Brown, Belinda
    Laws, Simon
    Maruff, Paul
    Salvado, Olivier
    Ames, David
    Martins, Ralph N.
    Masters, Colin L.
    Rowe, Christopher C.
    Villemagne, Victor L.
    LANCET NEUROLOGY, 2016, 15 (10): : 1044 - 1053
  • [5] Aptamarker prediction of brain amyloid-β status in cognitively normal individuals at risk for Alzheimer's disease
    Penner, Gregory
    Lecocq, Soizic
    Chopin, Anaelle
    Vedoya, Ximena
    Lista, Simone
    Vergallo, Andrea
    Cavedo, Enrica
    Lejeune, Francois-Xavier
    Dubois, Bruno
    Hampel, Harald
    PLOS ONE, 2021, 16 (01):
  • [6] Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels
    Tort-Merino, Adria
    Olives, Jaume
    Leon, Maria
    Penaloza, Claudia
    Valech, Natalia
    Santos-Santos, Miguel A.
    Camara, Estela
    Gronholm-Nyman, Petra
    Martinez-Lage, Pablo
    Fortea, Juan
    Molinuevo, Jose L.
    Sanchez-Valle, Raquel
    Laine, Matti
    Rodriguez-Fornells, Antoni
    Rami, Lorena
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 70 (01) : 211 - 225
  • [7] Incidence of cognitively defined late-onset Alzheimer's dementia subgroups from a prospective cohort study
    Crane, Paul K.
    Trittschuh, Emily
    Mukherjee, Shubhabrata
    Saykin, Andrew J.
    Sanders, R. Elizabeth
    Larson, Eric B.
    McCurry, Susan M.
    McCormick, Wayne
    Bowen, James D.
    Grabowski, Thomas
    Moore, Mackenzie
    Bauman, Julianna
    Gross, Alden L.
    Keene, C. Dirk
    Bird, Thomas D.
    Gibbons, Laura E.
    Mez, Jesse
    ALZHEIMERS & DEMENTIA, 2017, 13 (12) : 1307 - 1316
  • [8] Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study
    Gordon, Brian A.
    Blazey, Tyler M.
    Su, Yi
    Hari-Raj, Amrita
    Dincer, Aylin
    Flores, Shaney
    Christensen, Jon
    McDade, Eric
    Wang, Guoqiao
    Xiong, Chengjie
    Cairns, Nigel J.
    Hassenstab, Jason
    Marcus, Daniel S.
    Fagan, Anne M.
    Jack, Clifford R., Jr.
    Hornbeck, Russ C.
    Paumier, Katrina L.
    Ances, Beau M.
    Berman, Sarah B.
    Brickman, Adam M.
    Cash, David M.
    Chhatwal, Jasmeer P.
    Correia, Stephen
    Forster, Stefan
    Fox, Nick C.
    Graff-Radford, Neill R.
    la Fougere, Christian
    Levin, Johannes
    Masters, Colin L.
    Rossor, Martin N.
    Salloway, Stephen
    Saykin, Andrew J.
    Schofield, Peter R.
    Thompson, Paul M.
    Weiner, Michael M.
    Holtzman, David M.
    Raichle, Marcus E.
    Morris, John C.
    Bateman, Randall J.
    Benzinger, Tammie L. S.
    LANCET NEUROLOGY, 2018, 17 (03): : 241 - 250
  • [9] Could Altered Evoked Pain Responsiveness Be a Phenotypic Biomarker for Alzheimer's Disease Risk? A Cross-Sectional Analysis of Cognitively Healthy Individuals
    Romano, Raymond R.
    Carter, Michael A.
    Dietrich, Mary S.
    Cowan, Ronald L.
    Bruehl, Stephen P.
    Monroe, Todd B.
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 79 (03) : 1227 - 1233
  • [10] Cognitive Dispersion Is Not Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Results from the European Prevention of Alzheimer's Dementia (EPAD) v500.0 Cohort
    Watermeyer, Tam
    Marroig, Alejandra
    Ritchie, Craig W.
    Ritchie, Karen
    Blennow, Kaj
    Muniz-Terrera, Graciela
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 78 (01) : 185 - 194